

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CONJUPRO BIOTHERAPEUTICS, INC.,
Petitioner,

v.

ASCLETIS PHARMA CHINA CO. LTD.,
Patent Owner.

Case No. PGR2025-00057

Patent No. 12,234,236

Title: GLP-1R agonist and therapeutic method thereof

PATENT OWNER'S UPDATED EXHIBIT LIST

Exhibit No.	Description of Document
2001	Declaration of Geoffrey D. Biegler (“Biegler”)
2002	Excerpts of File History of U.S. Patent No. 12,234,236
2003	Excerpts of File History of U.S. Patent Application No. 18/885,065
2004	International Publication No. WO 2025/131043A1
2005	Certified English Translation of International Publication No. WO 2025/131043A1
2006	U.S. Patent No. 12,291,530
2007	Guang Huang et al., <i>Applications of Oxetanes in Drug Discovery and Medicinal Chemistry</i> , European Journal of Medicinal Chemistry (2023), 261
2008	Juan J. Rojas and James A. Bull, <i>Oxetanes in Drug Discovery Campaigns</i> , Journal of Medicinal Chemistry (2023), 66 , 12697-12709
2009	Jonas Boström et al., <i>Oxadiazoles in Medicinal Chemistry</i> , Journal of Medicinal Chemistry (2011), 55, 1817-1830
2010	Yijing Li et al., <i>Thiadiazole—a Promising Structure in Medicinal Chemistry</i> , ChemMedChem (2013), 27-41
2011	Bethany R. Shire and Edward A. Anderson, <i>Conquering the Synthesis and Functionalization of Bicyclo[1.1.1]pentanes</i> , An Open Access Journal of the American Chemical Society (2023), 3, 1539-1553
2012	Edon Vitaku, David T. Smith, and Jon T. Njardarson, <i>Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals</i> , Journal of Medicinal Chemistry (2014), 57, 10257-10274
2013	Marcelo D. Polêto et al., <i>Aromatic Rings Commonly Used in Medicinal Chemistry: Force Fields Comparison and Interactions With Water Toward the Design of New Chemical Entities</i> , Frontiers in Pharmacology (2018), 9, 1-20
2014	Aimee K. Clarke and William P. Unsworth, <i>A happy medium: the synthesis of medicinally important medium-sized rings via ring expansion</i> , The Royal Society of Chemistry (2020), 11, 2876-2881
2015	Alexander S. Harmata, Madison J. Sowden, and Corey R. J. Stephenson, <i>Bridged bicyclic building block upgrading:</i>

Exhibit No.	Description of Document
	<i>Photochemical synthesis of bicyclo[3.1.1]heptan-1-amines</i> , Willard Henry Dow Laboratory, Dept. of Chemistry, Univ. of Michigan
2016	Jang Won Son and Soo Lim, <i>Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management</i> , Endocrinology and Metabolism (2024), 39, 206-221
2017	Sean Wharton, M.D. et al., <i>Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity</i> , The New England Journal of Medicine (2023), 389, 877-888
2018	<i>A Study of Orforglipron (LY3502970) in Adult Participants with Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)</i> , Lilly Trials, https://trials.lilly.com/en-US/trial/403875 (last visited Oct. 6, 2025)
2019	International Publication No. WO 2024/169952 A1
2020	International Publication No. WO 2023/016546 A1
2021	International Publication No. WO 2024/153070 A1
2022	<i>Ascletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting</i> , Ascletis, https://www.ascletis.com/news_detail/192/id/1243.html (last visited Oct. 6, 2025)
2023	Jinzi Jason Wu and Vanessa Wang, <i>Poster number: 750-P, ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity -A First-in-Human Single Ascending Dose Study</i> , (June 20, 2025), https://www.ascletis.com/data/upload/ueditor/20250618/ASC30_poster_@_ADA_2025.pdf
2024	<i>Compound Summary for CID 8028, Tetrahydrofuran</i> , National Center for Biotechnology Information, PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Tetrahydrofuran
2025	<i>Compound Summary for CID 9253, Cyclopentane</i> , National Center for Biotechnology Information, PubChem,

Exhibit No.	Description of Document
	https://pubchem.ncbi.nlm.nih.gov/compound/Cyclopentane (last visited Oct. 6, 2025)
2026	Arun K Ghosh and David D Anderson, <i>Tetrahydrofuran, Tetrahydropyran, Triazoles and Related Heterocyclic Derivatives as Hiv Protease Inhibitors</i> , Future Med Chem. (2011), 3, 1181-1197
2027	Seung-Hwa Kwak et al., <i>Evaluation of Manassantin A Tetrahydrofuran Core Region Analogues and Cooperative Therapeutic Effects with EGFR Inhibition</i> , Journal of Medicinal Chemistry (2020), 63, 6821-6833
2028	Pedro de Sena Murteira Pinheiro, Lucas Silva Franco and Carlos Alberto Manssour Fraga, <i>The Magic Methyl and Its Tricks in Drug Discovery and Development</i> , MDPI (2023), 16, 1157
2029	Declaration of Isha Agarwal (“Agarwal”)
2030	Bio of Tae Yeon (Zoe) Kim (“Kim Bio”)
2031	Declaration of Tae Yeon (Zoe) Kim (“Kim”)

Dated: January 26, 2026

Respectfully submitted,

COOLEY LLP

ATTN: Patent Group
1299 Pennsylvania Ave., NW
Suite 700
Washington, D.C. 20004-2400
Tel: (858) 550-6019
Fax: (858) 550-6420

By: /Geoffrey D. Biegler/
Geoffrey D. Biegler (Admitted *pro hac vice* (37 CFR § 42.10(c)(2)))
W. Chad Shear
Reg. No. 47,938
Lead Attorney for Patent Owner

CERTIFICATION OF SERVICE UNDER 37 C.F.R. §§ 42.6(e), 42.105(a))

I, Geoffrey D. Bielger, hereby certify that on this 26th day of January, 2026,
the foregoing **PATENT OWNER'S UPDATED EXHIBIT LIST** was served
electronically via email on the following:

Jin Zhu, Ph.D.
Joe G. Chen, Ph.D.
FOX ROTHSCHILD LLP
212 Carnegie Center, Suite 400
Princeton, NJ 08540
jzhu@foxrothschild.com
joechen@foxrothschild.com

Luke Toft
FOX ROTHSCHILD LLP
33 South 6th Street, Suite 3600
Minneapolis, MN 55402
ltoft@foxrothschild.com

Dated: January 26, 2026

COOLEY LLP
ATTN: Patent Group
1299 Pennsylvania Ave., NW
Suite 700
Washington, D.C. 20004-2400
Tel: (858) 550-6019
Fax: (858) 550-6420

By: /Geoffrey D. Biegler/
Geoffrey D. Biegler (Admitted *pro hac*
vice (37 CFR § 42.10(c)(2)))
W. Chad Shear
Reg. No. 47,938
Lead Attorney for Patent Owner